Systemic Autoimmune Features and Multiple Sclerosis

Tourbah, Ayman; Clapin, Alexis; Gout, Olivier; Fontaine, Bertrand; Liblau, Roland; Batteux, Frédéric; Stievenart, J.L.; Weill, Bernard; Lubetzki, Catherine; Lyon-Caen, O.

doi:10.1001/archneur.55.4.517

Cited by 92 publications

(93 citation statements)

References 38 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of our study are in accordance with the investigations of Tournah et al [18] and Liedorp et al [25] who found low prevalence of ACL and B2GPI in MS patients, mainly IgM class. Many authors have suggested that the clinical features of MS could mimic APS.…”

Section: Discussionsupporting

confidence: 93%

“…Some authors suggest that the detection of APL could have diagnostic and prognostic significance; however the data from the literature is very heterogenic. Some authors found positive anticardiolipin antibodies (ACL) in 5.3% [17] and 6.2% [18] of the studied MS patients. Sugyama and Yamamoto [19] detected IgM ACL in 44% and IgG ACL in 9% of MS patients.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Annexin V antibodies in multiple sclerosis and SLE/APS

et al. 2013

View full text Add to dashboard Cite

AbstractMultiple sclerosis (MS) is an autoimmune disease with unclear etiopathogenesis. Some MS patients have anticardiolipin (ACL), anti-beta-2-glycoprotein-I (B2GPI) and anti-annexin V (AnV) antibodies. These antibodies can also be found in systemic lupus erythematosus with antiphospholipid syndrome (SLE/APS). The aim of our study was to compare the levels of ACL, B2GPI and AnV antibodies in MS and SLE/APS. Materials and methods: We investigated serum levels of IgG and IgM ACL, B2GPI and AnV in 21 MS patients, 30 SLE/APS patients and 30 controls using ELISA. Results: Mean levels of IgM and IgG ACL and B2GPI in MS were comparable with controls and lower than SLE/APS (p<0.05). Mean levels of IgM AnV in MS were higher compared to SLE/APS and controls (p<0.05); mean levels of IgG AnV in MS were higher than normal but similar to SLE/APS (p>0.05). Discussion: The results show that MS with negative “classic” autoantibodies (ACL and B2GPI) and without clinical data for antiphospholipid syndrome may have other positive antiphospholipid antibodies, such as AnV. Larger studies are needed to clarify whether AnV are epiphenomenon of the vascular and organ damage or they play a pathogenic role in the development of MS.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 98%

Annexin V antibodies in multiple sclerosis and SLE/APS

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The frequency of antinuclear antibodies ANA in patients with clinically definite MS varies from 2.5% to 81% of sera according to the study [5][6][7][8][9][10][11]. Most of these studies found no correlation between the presence of ANA and symptoms of SLE, although a correlation between ANA and MS disease activity was observed by Collard et al [10].…”

Section: Discussionmentioning

confidence: 97%

“…Recent studies showed a prevalence of aCl in MS patients of 4.8-44% of cases [11][12][13][14][15][16].…”

Section: Discussionmentioning

confidence: 99%

Do we need broad immunological work-up in all patients with CIS?

Adamec

Bošković

Škvorc

et al. 2012

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…Few studies examined comorbidity and MS. [3][4][5][6] Studies of autoimmune disease and MS did not identify any effect of autoimmune disease on clinical features or outcomes of MS. [3][4][5] Reports conflict regarding the association between smoking and disability progression. 6,7 Potential benefits of studying comorbidity in MS include improved prognostication; insights into the etiology and pathogenesis of MS; and the treatment of comorbidities as an avenue for improving outcomes.…”

Section: 2mentioning

confidence: 99%